当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
The New England Journal of Medicine ( IF 74.699 ) Pub Date : 2019-09-28 , DOI: 10.1056/nejmoa1909707
Robert L Coleman,Gini F Fleming,Mark F Brady,Elizabeth M Swisher,Karina D Steffensen,Michael Friedlander,Aikou Okamoto,Kathleen N Moore,Noa Efrat Ben-Baruch,Theresa L Werner,Noelle G Cloven,Ana Oaknin,Paul A DiSilvestro,Mark A Morgan,Joo-Hyun Nam,Charles A Leath,Shibani Nicum,Andrea R Hagemann,Ramey D Littell,David Cella,Sally Baron-Hay,Jesus Garcia-Donas,Mika Mizuno,Katherine Bell-McGuinn,Danielle M Sullivan,Bruce A Bach,Sudipta Bhattacharya,Christine K Ratajczak,Peter J Ansell,Minh H Dinh,Carol Aghajanian,Michael A Bookman

BACKGROUND Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. METHODS In an international, phase 3, placebo-controlled trial, we assessed the efficacy of veliparib added to first-line induction chemotherapy with carboplatin and paclitaxel and continued as maintenance monotherapy in patients with previously untreated stage III or IV high-grade serous ovarian carcinoma. Patients were randomly assigned in a 1:1:1 ratio to receive chemotherapy plus placebo followed by placebo maintenance (control), chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only), or chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout). Cytoreductive surgery could be performed before initiation or after 3 cycles of trial treatment. Combination chemotherapy was 6 cycles, and maintenance therapy was 30 additional cycles. The primary end point was investigator-assessed progression-free survival in the veliparib-throughout group as compared with the control group, analyzed sequentially in the BRCA-mutation cohort, the cohort with homologous-recombination deficiency (HRD) (which included the BRCA-mutation cohort), and the intention-to-treat population. RESULTS A total of 1140 patients underwent randomization. In the BRCA-mutation cohort, the median progression-free survival was 34.7 months in the veliparib-throughout group and 22.0 months in the control group (hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 0.28 to 0.68; P<0.001); in the HRD cohort, it was 31.9 months and 20.5 months, respectively (hazard ratio, 0.57; 95 CI, 0.43 to 0.76; P<0.001); and in the intention-to-treat population, it was 23.5 months and 17.3 months (hazard ratio, 0.68; 95% CI, 0.56 to 0.83; P<0.001). Veliparib led to a higher incidence of anemia and thrombocytopenia when combined with chemotherapy as well as of nausea and fatigue overall. CONCLUSIONS Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliparib maintenance therapy led to significantly longer progression-free survival than carboplatin plus paclitaxel induction therapy alone. The independent value of adding veliparib during induction therapy without veliparib maintenance was less clear. (Funded by AbbVie; VELIA/GOG-3005 ClinicalTrials.gov number, NCT02470585.).
更新日期:2019-12-19

 

全部期刊列表>>
胸部和胸部成像专题
自然科研论文编辑服务
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
鲁照永
华东师范大学
苏州大学
南京工业大学
南开大学
中科大
唐勇
跟Nature、Science文章学绘图
隐藏1h前已浏览文章
中洪博元
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
x-mol收录
广东实验室
南京大学
王杰
南科大
刘尊峰
湖南大学
清华大学
王小野
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug